3 Biotech Stocks That Could Make Your Summer Unforgettable

Core Insights - The article discusses potential investment opportunities in biotech stocks, particularly focusing on companies like Structure Therapeutics (GPCR), Cybin (CYBN), Eli Lilly (LLY), and Syndax Pharma (SNDX) based on upcoming FDA decisions and trial results [2][4][22]. Group 1: Structure Therapeutics (GPCR) - GPCR is expected to report Phase 2a 12-week obesity drug data in Q2, with positive Phase 1 results raising expectations for solid Phase 2 outcomes [2]. - The stock price of GPCR was approximately $36.80 prior to the anticipated data release, which is expected on June 3 [2]. - Following the release of positive top-line Phase 2a data, the stock reached a high of $62.74, indicating significant potential for profit through anticipation trading [15]. Group 2: Cybin (CYBN) - The FDA is set to decide on the approval of MDMA-assisted therapy for PTSD on August 11, which could positively impact psychedelic stocks like Cybin [4][9]. - A recent study indicated that MDMA reduced PTSD symptoms in 86% of participants after 18 weeks, although an FDA panel voted against approval due to concerns about trial execution [8][9]. Group 3: Eli Lilly (LLY) - Eli Lilly's Zepbound drug is under consideration for the treatment of obstructive sleep apnea, with an FDA decision expected before the end of the year [19]. - The company anticipates that FDA approval could benefit the 80 million Americans suffering from obstructive sleep apnea, and the stock is currently viewed as oversold [18][19]. Group 4: Syndax Pharma (SNDX) - The FDA will decide on Syndax Pharma's axatilimab for chronic graft-versus-host disease (GVHD) on August 28, following two previous systemic therapy failures [21]. - Analysts from Jefferies and Stifel have initiated Buy ratings on SNDX, with price targets of $37 and $42 respectively, citing the company's potential for commercialization [22].